Buprenorphine binds to opioid receptors far more tightly than oxycodone, and milligram for milligram, it is roughly 20 to 30 times more potent. But “stronger” doesn’t tell the whole story, because buprenorphine is a partial activator of those receptors. It grips them with exceptional force yet only partially switches them on, which creates a ceiling on its effects that oxycodone, a full activator, does not have.
Understanding the difference matters whether you’re managing pain, transitioning between medications, or simply trying to make sense of two drugs that get compared often but work in fundamentally different ways.
Binding Strength vs. Actual Effect
The confusion around potency comes from conflating two things: how tightly a drug attaches to a receptor and how much it activates that receptor once attached. Buprenorphine wins the first contest by a wide margin. Its binding affinity at the mu-opioid receptor is measured at a Ki value of about 0.216 nanomolar, compared to 25.9 nanomolar for oxycodone. A lower Ki means a tighter grip, so buprenorphine clings to the receptor roughly 120 times more tightly than oxycodone does.
That tight binding is why buprenorphine can block other opioids from taking effect. Once it occupies the receptor, drugs like oxycodone, morphine, or heroin have a very hard time displacing it. This property is central to its role in treating opioid use disorder.
But activation is a separate question. Oxycodone is a full agonist, meaning it fully switches on the mu receptor and its effects keep climbing with higher doses: more pain relief, more sedation, more respiratory depression. Buprenorphine only partially activates the same receptor. At a certain dose, its pain-relieving and breathing-suppressing effects plateau, no matter how much more you take. Researchers confirmed this in a study of healthy volunteers given two different intravenous doses. Doubling the dose increased pain relief but did not increase respiratory depression, demonstrating that the ceiling is real and appears at clinically relevant doses.
How Potency Is Measured in Practice
Clinicians compare opioid strength using morphine milligram equivalents (MME). One milligram of oral oxycodone converts to 1.5 MME. One milligram of buprenorphine in tablet or film form converts to 30 MME. By that standard, buprenorphine is 20 times more potent than oxycodone on a milligram-to-milligram basis. Buprenorphine patches, dosed in micrograms per hour, use a separate conversion factor of 12.6 per microgram.
These conversion factors reflect the amount of drug needed to produce a roughly equivalent level of pain relief at lower doses. They do not mean buprenorphine produces 20 times the “high” or 20 times the danger. Because of its partial agonism, buprenorphine’s maximum possible effect is lower than what a full agonist like oxycodone can produce at sufficiently high doses.
The Ceiling Effect and Safety
The ceiling effect is the single most important practical difference between these two drugs. With oxycodone, taking too much can slow breathing to a fatal stop. That dose-dependent respiratory depression is the primary way opioid overdoses kill. Buprenorphine’s breathing suppression levels off, which makes fatal overdose from buprenorphine alone far less likely than overdose from oxycodone or other full agonists.
This safety advantage has limits. Combining buprenorphine with benzodiazepines, alcohol, or other sedatives can still cause dangerous respiratory depression. And the ceiling effect on breathing does not mean the ceiling on pain relief is identical. Early research suggested that pain relief also plateaus, but the study of two intravenous doses found that analgesia continued to increase even as respiratory depression did not. The clinical picture is that buprenorphine offers a wider margin of safety between an effective pain-relieving dose and a dose that threatens breathing.
Why Buprenorphine Is Harder to Reverse
That extraordinarily tight receptor binding creates a complication in emergencies. Naloxone, the standard opioid reversal agent, works by knocking opioids off their receptors. With oxycodone, a standard dose of 0.4 to 2 milligrams of naloxone typically reverses an overdose effectively. With buprenorphine, those doses often have no meaningful effect.
Reversing buprenorphine’s respiratory effects can require 2.5 to 10 milligrams of naloxone, and even then, reversal is often only partial. Some case reports describe outright resistance to naloxone. This doesn’t mean buprenorphine is more dangerous overall. It means that in the uncommon scenario of a buprenorphine-related breathing emergency, the rescue process is more complicated and may require repeated higher doses.
Switching From Oxycodone to Buprenorphine
If you’re transitioning from oxycodone to buprenorphine, timing matters enormously. Because buprenorphine binds so tightly but only partially activates receptors, taking it while oxycodone still occupies your receptors can trigger precipitated withdrawal. This is a rapid, intense onset of withdrawal symptoms, far worse than the gradual withdrawal that happens when you simply stop taking an opioid.
Guidelines recommend waiting until you’re in moderate to severe withdrawal before starting buprenorphine, typically 6 to 24 hours after your last oxycodone dose. Clinicians measure withdrawal severity using a standardized scoring system called COWS (Clinical Opiate Withdrawal Scale). More recent recommendations suggest waiting until a COWS score reaches at least 13 before starting buprenorphine, a higher threshold than earlier guidelines set, based on cases where precipitated withdrawal occurred at lower scores.
The practical experience of precipitated withdrawal is severe enough that getting this timing wrong can erode trust in treatment. If you’re making this transition, it will be closely managed, and the discomfort of waiting for adequate withdrawal to set in is a deliberate part of the process.
A Unique Side Effect of Sublingual Forms
Buprenorphine tablets and films that dissolve in the mouth carry a risk that oxycodone (swallowed as a pill) does not: dental damage. The FDA issued a warning after reports of serious tooth decay, cavities, oral infections, and tooth loss in patients using these formulations, including people with no prior dental problems. The issue is specific to the sublingual tablets approved in 2002 and the buccal films approved in 2015, not to buprenorphine patches or injections. If you use a dissolving form of buprenorphine, rinsing your mouth with water after the medication fully dissolves and waiting at least an hour before brushing can help reduce the risk.
So Which One Is “Stronger”?
Buprenorphine is more potent per milligram and binds to opioid receptors with far greater tenacity. In those senses, it is stronger. But it produces less maximum effect than oxycodone because it only partially activates those receptors. At low to moderate doses, buprenorphine delivers powerful pain relief. At high doses, its effects flatten out while oxycodone’s continue to escalate.
This makes the comparison less about which drug is “stronger” and more about which drug does what. Oxycodone is a straightforward, fully activating pain reliever with escalating effects and escalating risks. Buprenorphine is a high-affinity partial activator with a built-in safety ceiling, used both for pain management and for blocking the effects of other opioids in addiction treatment. They occupy different roles precisely because their strengths are different kinds of strength.